Open AccessRomosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Author(s) -
Kenneth G. Saag,
Jeffrey Petersen,
Maria Luisa Brandi,
Andrew C. Karaplis,
Mattias Lorentzon,
Thierry Thomas,
Judy Maddox,
Michelle Fan,
Paul Meisner,
Andreas Grauer
Publication year - 2017
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1708322
Subject(s) - medicine , sclerostin , osteoporosis , alendronic acid , incidence (geometry) , cumulative incidence , bone resorption , surgery , dentistry , bisphosphonate , cohort , biochemistry , wnt signaling pathway , chemistry , physics , optics , gene
Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom